comprehensive -WSS

comprehensive

author：focus 2025-09-29 23:03:56 - browse：277

Illustration of a dollar sign with arrows. — Adobe

Health insurers are telling shareholders that they are ramping up the use of artificial intelligence and are hiring talent to implement the technology across their organizations. They say their artificial intelligence models can increase efficiency and “cut costs,” but they refused to discuss what models they’re using, how those models were developed, or exactly what they’re using them for.

Centene, for instance, says, it is “investing in artificial intelligence and machine learning technologies to improve the health of our members and contain rising healthcare costs.” The insurer, whose plans cover more than 28 million Americans, noted that its large footprint, particularly in government-sponsored programs, puts it “in a unique position to use data to develop models that predict a wide range of health outcomes.”

A STAT review of regulatory filings from publicly traded health insurers showed that several of them, including Elevance, Molina, and Cigna, are investing in AI with the goal of saving money. Elevance has hired nearly 500 people to work exclusively on AI. However, all five of the insurers STAT contacted declined to elaborate on how they are using AI.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Drug for rare kidney disease narrowly misses mark in clinical trial

focus

WSS

Search called off for baby washed away in Pennsylvania flash flood

Will the FTC rein in IQVIA's health data empire?

New Alzheimer's drugs heat up race for early detection blood tests

Senate panel puts off hardest PBM reforms for another day

Device maker Teleflex to acquire urology company for $600M

Hearing on Medicare drug price negotiation gets unusually heated

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biotech stock slump in 2023: awaiting the turnaround

Guidelines to prevent youth baseball injuries need more muscle

Dems pitch expanding Medicare power to negotiate drug prices

Heart attack and stroke risk calculators need revising

Thermo Fisher plant for manufacturing gene therapies to expand

What does generative AI mean for health care? We asked experts

Dems pitch expanding Medicare power to negotiate drug prices

Sports medicine is finally prioritizing gender equality

Biotech lab space demand falls sharply

hotspot

Dems pitch expanding Medicare power to negotiate drug prices

CommonSpirit Health keeps growing, even as it loses money

EpiPen alternative approval delay highlights citizen petition issue

Lasker Awards 2023: Winners in biomedical research

Democrats decry new health bill for going easy on private equity

Truvian presents data for its desktop blood

focus

hotspot

focus

focus